Sensyne Health PLC (LON:SENS) announced it is mulling over a potential dual listing on Nasdaq.
The ethical patient data company said it would complement its primary listing on AIM as it is committed to keeping its headquarters in the UK.
READ: Sensyne Health appoints former MHRA boss as an independent director
It added that it continues to explore strategic opportunities, including making acquisitions in line with its objectives and its established strategic research agreements with the NHS and US health systems.
Its strategy is centred on the ethical use of real-world patient data to support advances in medical and life science research for the benefit of patients.
The group recently signed two agreements with US health systems: St. Luke's University Health Network in Pennsylvania and the Colorado Center for Personalized Medicine.
It now has access to 18.2mln unique patient records, 8.4mln of which are in the UK and the rest in the US, representing more than a 600% increase in size since September 2020. Sensyne aims to build an ethically sourced real-world dataset of 100mln patient records by the end of 2024.
The ‘double bottom line’ business model includes working in partnership with healthcare providers that receive a financial return through equity ownership in Sensyne and a share of revenues.
"Now is the time for Sensyne to build on the success of its unique business model that has already created one of the world's fastest-growing patient data resources for life-sciences research,” said Lord Drayson, founder and chief executive of Sensyne.
“Our model provides a clear competitive advantage in terms of our commitment to patient data privacy, our close and collaborative research with our partners and our fair and transparent financial arrangements where we share the wealth that we create with the health systems that work with us.”
Broker Peel Hunt said: "We agree with the company: Sensyne has become one of the world’s fastest growing patient data resources (with circa 18.2mln unique patient records, 8.4mln NHS/UK and 9.8mln US), and the business model/offering has found traction in both US and UK healthcare systems as well as with a number of global pharma companies (Roche, Bayer, Alexion, BMS etc)."